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CASE REPORT
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Background Occupational diisocyanate-induced extrinsic allergic alveolitis (EAA) is a rare and probably under-
estimated diagnosis. Two acute occupational EAA cases have been described in this context, but nei-
ther of them concerned hexamethylene diisocyanate (HDI) exposure.
Aims To investigate the cause of a life-threatening EAA arising at work in a healthy 30-year-old female paint
quality controller.
Methods Occupational medical assessment, workplace evaluation, airborne and biological monitoring and im-
munodermatological tests.
Results Diagnosis of EAA relied on congruent clinical and radiological information, confirmed occupational
HDI exposure and positive IgG antibodies and patch tests. The patient worked in a small laboratory
for 7 years, only occasionally using HDI-containing hardeners. While working with HDI for 6 h, she
developed breathlessness, rapidly progressing to severe respiratory failure. Workplace HDI airborne
exposure values ranged from undetectable levels to 4.25 p.p.b. Biological monitoring of urinary
hexamethylene diamine in co-workers ranged from,1.0 to 15.4 mg/g creatinine. Patch tests 8 months
later showed delayed skin reaction to HDI at 48 h. Subsequent skin biopsy showed spongiotic
dermatitis with infiltration of CD41 and CD81 T cells.
Conclusions We believe this is the first reported case of acute life-threatening EAA following exposure to HDI. Low
concentrations of airborne HDI and relatively high urinary hexamethylene diamine suggest significant
skin absorption of HDI could have significantly contributed to the development of this acute occu-
pational EAA.
Key words Hexamethylene diisocyanate; occupational extrinsic allergic alveolitis (EAA); occupational hyper-
sensitivity pneumonitis; paint quality control.
Introduction
As haptens, isocyanates can induce different humoral
(IgE and IgG) and cellular (T-cell) immune mechanisms.
Clinically, these reactions can cause allergic asthma and
extrinsic allergic alveolitis (EAA) or hypersensitivity
pneumonitis, presumably through both type-III and
type-IV immunity [1].
Few cases of isocyanate-induced occupational EAA
have been reported [2–5], and most are subacute or
chronic forms, affecting workers in car body repair shops
[2, 3, 5] or polyurethane foam production [4].
Inhalation is considered the main route for isocyanate
exposure. However, human and animal studies suggest
respiratory sensitization and disease exacerbation from
dermal exposure [6].
We describe possibly the first reported case of acute
life-threatening occupational EAA related to hexamethy-
lene diisocyanate (HDI) exposure.
Case report
In June 2008, a 30-year-old healthy female paint quality
controller(5pack/yearssmoker)developedbreathlessness,
cough, chest tightness, malaise, sweating and chills in her
workplace. Severe respiratory failure (PaO2 5.6 kPa,
PaCO2 4.4 kPa) and hemoptysis followed rapidly. Exam-
ination revealed left basal and right mid-lung crackles,
respiratory rate of 24/min and temperature 37.6C.
Bloodtestfindings includedraisedC-reactiveprotein(11
mg/l), thrombocytopenia (71 G/l), raised liver enzymes
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(aspartate aminotransferase 124; alanine aminotransferase
140 U/l) but normal white cell count (5.8 G/l). Infection
and autoimmune and toxicology screening were negative.
Chest radiography showed diffuse bilateral infiltrates and
ground-glassappearanceonhigh-resolutioncomputerized
tomography,mainly in the basal lung fields, with thickened
interlobular septa on both apical sides (Figure 1).
Two hours after admission, sudden respiratory wors-
ening was treated with high concentration oxygen and
systemic corticosteroids in the intensive care unit, with
rapid improvement. Oxygen was stopped at Day 3 and
radiographic abnormalities almost resolved by Day 5.
In September 2008, we performed a workplace investiga-
tion. The patient worked as a paint quality controller for 7
years, mixing small specimens of acrylic paints. For up
to six non-consecutive weeks per year, she also dealt with
HDI-basedhardeners in thesameway.Sheusedshort latex
gloves but no respiratory protection or lab coat. On the day
of the acute event, she had been using an HDI-containing
hardener (70–80% HDI-based aliphatic polyisocyanate
and 0.1–0.5% hexamethylene-1, 6-diisocyanate mono-
mers) for 6 h when the first symptom occurred.
In the laboratory, only two employees work as paint
controllers in a separate room. Neither the second paint
controller nor the 10 coworkers reported any respiratory
symptoms. Air renewal rate was 1.5 times/h. To avoid po-
tential toxic isocyanate exposure, this should be at least 10
times higher. We measured HDI-air exposure and col-
lected urine samples from two other paint controllers, af-
ter a 45-min work session using the same paints as on the
day of the incident. Stationary HDI air exposure values
ranged from undetectable to 4.25 p.p.b. Personal ones
were all undetectable (,0.05 p.p.b.). Urine samples were
collected for three other people present during the work
simulation. Urinary 1,6-hexamethylene diamine, consid-
ered to be the most sensitive biomarker of HDI exposure
[7], ranged from ,1.0 to 15.4 mg/g creatinine (controller
1: 5.1, controller 2:,1.0, line manager: 4.0, investigation
team member 1: ,1.0 and 2, who had slight dermal con-
tact with HDI: 15.4).
In February 2009, immunological investigations in the
patient revealed raised specific IgG antibodies to HDI
(2.9 mg/l) and to 4.4-diphenylmethandiisocyanate (3.2
mg/l) but not to toluene-2.4-diisocyanate (,2 mg/l), spe-
cific IgE antibodies and a lymphocyte transformation test
were negative. Skin tests (prick, scratch and patch tests)
were performed with TDI (Fluka art 89870) and HDI
(Merck art 822066) at a dilution of 1:10 in phosphate-
buffered saline (PBS; pH 7.4). PBS served as a negative
control. Prick and scratch tests were negative. Patch tests
showed a positive delayed skin reaction to HDI at 48 h. In
the next 2 weeks, the patient developed eczema around
her neck and shoulders, suggesting sensitization to
HDI. After 22 days, a skin biopsy showed spongiotic
dermatitis, with CD41 T cells infiltrating the dermis
and CD81 T cells lying at the dermo-epidermal junction
and in the epidermis compatible with a T-cell-mediated-
delayed hypersensitivity reaction to HDI.
Discussion
This case suggests that low-level airborne HDI and pos-
sibly dermal exposure can cause EAA, possibly mediated
by activated T cells.
The differential diagnosis of an acute respiratory event
like this includes hemorrhagic pneumonitis, acute respi-
ratory distress syndrome and idiopathic eosinophilic
pneumonia. As neither bronchoalveolar lavage nor spe-
cific immunoglobulin tests were performed at the time
of the incident, we performed occupational and immuno-
logical investigations and supported the diagnosis of EAA
by using the clinical criteria of Lacasse et al. [8]. The fol-
lowing criteria apply in this case: (i) exposure to a known
offending antigen, (ii) symptoms 4–8 h after exposure,
(iii) respiratory crackles and (iv) positive serum precipi-
tins. Criteria (v) recurrent episodes and (vi) weight loss
did not apply in this case, but the probability of EAA
is still 90%. As the incident was life threatening, we
did not risk re-exposure or specific challenge test.Figure 1. High-resolution computerized tomography at Day 1.
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The moderate levels of IgG antibodies to HDI may re-
flect the lack of re-exposure to HDI for .6 months. The
precise biological and clinical relevance of specific IgG in
EAA remains unclear [1]. Allergy tests revealed a strong
delayed-type reaction to isocyanates, which is character-
istic for T-cell sensitization. Previous studies indicate that
cellular hypersensitivity, including activated T cells may
be relevant in the pathogenesis of EAA [9]. We observed
marked infiltration of CD81 T cells at the dermo-epider-
mal junction and in the epidermis. Thus, in addition to
inducing contact dermatitis, T cells may also infiltrate
the lung and mediate alveolitis.
Low levels of airborne isocyanate exposure sug-
gested that dermal contact might have significantly con-
tributed to total body uptake, as suggested by recent
studies [10], highlighting the importance of biological
monitoring.
Acknowledgements
The authors thank M. Berode and R. Llano for their helpful col-
laboration on this study.
Conflicts of interest
None declared.
References
1. Girard M, Lacasse Y, Cormier Y. Hypersensitivity pneumo-
nitis. Allergy 2009;64:322–334.
2. Nakashima K, Takeshita T, Morimoto K. Occupational hy-
persensitivity pneumonitis due to isocyanates: mechanisms
of action and case reports in Japan. Ind Health 2001;39:
269–279.
3. Schreiber J, Knolle J, Sennekamp J et al. Sub-acute occupa-
tionalhypersensitivitypneumonitisdue to low-level exposure
todiisocyanates inasecretary.EurRespir J2008;32:807–811.
4. Merget R, Marczynski B, Chen Z et al. Haemorrhagic hy-
persensitivity pneumonitis due to naphthylene-1,5-diiso-
cyanate. Eur Respir J 2002;19:377–380.
5. Usui Y, Aida H, Kimula Y, Miura H, Takayama S,
Nakayama M. Hypersensitivity pneumonitis induced by
hexamethylene diisocyanate. Intern Med 1992;31:912–916.
6. Bello D, Herrick CA, Smith TJ et al. Skin exposure to iso-
cyanates: reasons for concern. Environ Health Perspect
2007;115:328–335.
7. Maitre A, Berode M, Perdrix A, Stoklov M, Mallion JM,
Savolainen H. Urinary hexane diamine as an indicator of
occupational exposure to hexamethylene diisocyanate. Int
Arch Occup Environ Health 1996;69:65–68.
8. Lacasse Y, Selman M, Costabel U et al. Clinical diagnosis of
hypersensitivity pneumonitis. Am J Respir Crit Care Med
2003;168:952–958.
9. Raulf-Heimsoth M, Baur X. Pathomechanisms and patho-
physiology of isocyanate-induced diseases—summary of
present knowledge. Am J Ind Med 1998;34:137–143.
10. Bello D, Redlich CA, Stowe MH et al. Skin exposure to
aliphatic polyisocyanates in the auto body repair and refin-
ishing industry: II. A quantitative assessment. Ann Occup
Hyg 2008;52:117–124.
Key points
• This case report suggests that low-level hexa-
methylene diisocyanate exposure may induce
life-threatening extrinsic allergic alveolitis.
• Hexamethylene diisocyanate skin absorption may
have been a significant route of exposure.
• Effective control of occupational diisocyanate expo-
sure requires both skin and respiratory protection.
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